Certified Advisory Corp’s Esperion Therapeutics ESPR Stock Holding History

Certified Advisory Corp’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$1K	Hold	28	–	–	﹤0.01%	721
2020 Q1	$1K	Sell	28 -25	-47%	-$1.32K	﹤0.01%	729
2019 Q4	$3K	Hold	53	–	–	﹤0.01%	694
2019 Q3	$2K	Hold	53	–	–	﹤0.01%	728
2019 Q2	$2K	Buy	53 +25	+89%	+$1.17K	﹤0.01%	742
2019 Q1	$1K	Hold	28	–	–	﹤0.01%	712
2018 Q4	$1K	Hold	28	–	–	﹤0.01%	707
2018 Q3	$1K	Hold	28	–	–	﹤0.01%	743
2018 Q2	$1K	Buy	+28	New	+$1.42K	﹤0.01%	732

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Certified Advisory Corp's ESPR Position: Q2 2020 in Review

Certified Advisory Corp held its Esperion Therapeutics (ESPR) position steady in Q2 2020 at 28 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #721.

Certified Advisory Corp first reported a position in ESPR in Q2 2018 and has held it in 9 quarters since. The position peaked at $3K in Q4 2019. 183 funds tracked by Wall St. Rank hold ESPR as of Q2 2020.

Certified Advisory Corp held 28 shares of Esperion Therapeutics worth $1K as of Q2 2020.
Certified Advisory Corp left its Esperion Therapeutics share count unchanged in Q2 2020.
Esperion Therapeutics made up ﹤0.01% of Certified Advisory Corp's portfolio in Q2 2020, its #721 holding.
Certified Advisory Corp first reported a position in Esperion Therapeutics in Q2 2018 and has held it in 9 quarters since.
Certified Advisory Corp's Esperion Therapeutics position peaked at $3K in Q4 2019.
183 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2020.

Based on Certified Advisory Corp's 13F filing for Q2 2020, filed 27 Jul 2020.